{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:37:06Z","timestamp":1792859826067,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009447","name":"Leukemia and Lymphoma Society of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019683","name":"Cole Foundation","doi-asserted-by":"publisher","award":["Doctoral Fellowship"],"award-info":[{"award-number":["Doctoral Fellowship"]}],"id":[{"id":"10.13039\/100019683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019683","name":"Cole Foundation","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100019683","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020986","name":"Fondation de l'H\u00f4pital g\u00e9n\u00e9ral juif","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/501100020986","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"FRSQ","doi-asserted-by":"crossref","award":["Clinical Junior Scientist"],"award-info":[{"award-number":["Clinical Junior Scientist"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000156","name":"FRSQ","doi-asserted-by":"crossref","award":["Junior Scientist"],"award-info":[{"award-number":["Junior Scientist"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000156","name":"FRSQ","doi-asserted-by":"crossref","award":["Postdoctoral Fellowship"],"award-info":[{"award-number":["Postdoctoral Fellowship"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chair","doi-asserted-by":"crossref","award":["Genome Stability and Hematological Malignancies"],"award-info":[{"award-number":["Genome Stability and Hematological Malignancies"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acute myeloid leukemia (AML) is an aggressive hematological cancer resulting from uncontrolled proliferation of differentiation-blocked myeloid cells. Seventy percent of AML patients are currently not cured with available treatments, highlighting the need of novel therapeutic strategies. A promising target in AML is the mammalian target of rapamycin complex 1 (mTORC1). Clinical inhibition of mTORC1 is limited by its reactivation through compensatory and regulatory feedback loops. Here, we explored a strategy to curtail these drawbacks through inhibition of an important\u00a0effector of the\u00a0mTORC1signaling pathway, the eukaryotic initiation factor 4A (eIF4A).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We tested the anti-leukemic effect of a potent and specific eIF4A inhibitor (eIF4Ai), CR-1-31-B, in combination with cytosine arabinoside (araC) or the BCL2 inhibitor venetoclax. We utilized the MOLM-14 human AML cell line to model chemoresistant disease both in vitro and in vivo. In eIF4Ai-treated cells, we assessed for changes in survival, apoptotic priming, de novo protein synthesis, targeted intracellular metabolite content, bioenergetic profile, mitochondrial reactive oxygen species (mtROS) and mitochondrial membrane potential (MMP).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>eIF4Ai exhibits anti-leukemia activity in vivo while sparing non-malignant myeloid cells. In vitro, eIF4Ai synergizes with two therapeutic agents in AML, araC and venetoclax. EIF4Ai reduces mitochondrial membrane potential (MMP) and the rate of ATP synthesis from mitochondrial respiration and glycolysis. Furthermore, eIF4i enhanced apoptotic priming while reducing the expression levels of the antiapoptotic factors BCL2, BCL-XL and MCL1. Concomitantly, eIF4Ai decreases intracellular levels of specific metabolic intermediates of the tricarboxylic acid cycle (TCA cycle) and glucose metabolism, while enhancing mtROS. In vitro redox stress contributes to eIF4Ai cytotoxicity, as treatment with a ROS scavenger partially rescued the viability of eIF4A inhibition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We discovered that chemoresistant MOLM-14 cells rely on eIF4A-dependent cap translation for survival in vitro and in vivo. EIF4A drives an intrinsic metabolic program sustaining bioenergetic and redox homeostasis and regulates the expression of anti-apoptotic proteins. Overall, our work suggests that eIF4A-dependent cap translation contributes to adaptive processes involved in resistance to relevant therapeutic agents in AML.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-022-02542-8","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T02:02:43Z","timestamp":1670551363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax"],"prefix":"10.1186","volume":"41","author":[{"given":"Katie","family":"Fooks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Galicia-Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Schcolnik-Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaynab","family":"Nouhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W. L.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan N.","family":"Rys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Aloyz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Orthwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hulea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5324-2167","authenticated-orcid":false,"given":"Francois E.","family":"Mercier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"7","key":"2542_CR1","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.","journal-title":"Blood Cancer J"},{"issue":"1","key":"2542_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","volume":"2016","author":"CD DiNardo","year":"2016","unstructured":"DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematol Am Soc Hematol Educ Program. 2016;2016(1):348\u201355.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"22","key":"2542_CR3","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"7","key":"2542_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"2542_CR5","doi-asserted-by":"publisher","first-page":"12700","DOI":"10.1038\/ncomms12700","volume":"7","author":"M Carbonneau","year":"2016","unstructured":"Carbonneau M, Gagn\u00e9 LM, Lalonde ME, Germain MA, Motorina A, Guiot MC, et al. The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nat Commun. 2016;7:12700.","journal-title":"Nat Commun"},{"issue":"26","key":"2542_CR6","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1182\/blood-2011-03-340273","volume":"117","author":"M Levis","year":"2011","unstructured":"Levis M. FLT3\/ITD AML and the law of unintended consequences. Blood. 2011;117(26):6987\u201390.","journal-title":"Blood"},{"issue":"1","key":"2542_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5(1):288.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2542_CR8","first-page":"98","volume":"80","author":"L Bensi","year":"1995","unstructured":"Bensi L, Longo R, Vecchi A, Messora C, Garagnani L, Bernardi S, et al. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica. 1995;80(2):98\u2013102.","journal-title":"Haematologica"},{"issue":"24","key":"2542_CR9","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1182\/bloodadvances.2019000937","volume":"3","author":"DA Pollyea","year":"2019","unstructured":"Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3(24):4326\u201335 Blood Adv. 2020;4(6):1020.","journal-title":"Blood Adv"},{"issue":"4","key":"2542_CR10","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536\u201351.","journal-title":"Cancer Discov"},{"issue":"12","key":"2542_CR11","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","volume":"34","author":"T Herold","year":"2020","unstructured":"Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34(12):3161\u201372.","journal-title":"Leukemia"},{"issue":"1","key":"2542_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-9-292","volume":"9","author":"W Chen","year":"2010","unstructured":"Chen W, Drakos E, Grammatikakis I, Schlette EJ, Li J, Leventaki V, et al. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer. 2010;9(1):1\u20137.","journal-title":"Mol Cancer"},{"issue":"5","key":"2542_CR13","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532\u201342.","journal-title":"Blood"},{"issue":"17","key":"2542_CR14","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/blood-2012-05-378596","volume":"120","author":"AF Ward","year":"2012","unstructured":"Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012;120(17):3397\u2013406.","journal-title":"Blood"},{"issue":"4","key":"2542_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4161\/15384101.2014.991572","volume":"14","author":"M Morita","year":"2015","unstructured":"Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, et al. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle. 2015;14(4):473\u201380.","journal-title":"Cell Cycle"},{"issue":"2","key":"2542_CR16","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1530\/JME-18-0058","volume":"62","author":"O Uchenunu","year":"2019","unstructured":"Uchenunu O, Pollak M, Topisirovic I, Hulea L. Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. J Mol Endocrinol. 2019;62(2):R83\u2013R103.","journal-title":"J Mol Endocrinol"},{"issue":"6","key":"2542_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.cmet.2018.09.001","volume":"28","author":"L Hulea","year":"2018","unstructured":"Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, et al. Translational and HIF-1alpha-dependent metabolic reprogramming underpin metabolic plasticity and responses to kinase inhibitors and biguanides. Cell Metab. 2018;28(6):817\u201332 e8.","journal-title":"Cell Metab"},{"issue":"1","key":"2542_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41467-020-20491-8","volume":"12","author":"T Oki","year":"2021","unstructured":"Oki T, Mercier F, Kato H, Jung Y, McDonald TO, Spencer JA, et al. Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML. Nat Commun. 2021;12(1):245.","journal-title":"Nat Commun"},{"issue":"11","key":"2542_CR19","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2017.81","volume":"31","author":"L Poulain","year":"2017","unstructured":"Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, et al. High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. Leukemia. 2017;31(11):2326\u201335.","journal-title":"Leukemia"},{"issue":"3","key":"2542_CR20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","volume":"102","author":"Q Xu","year":"2003","unstructured":"Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003;102(3):972\u201380.","journal-title":"Blood"},{"issue":"2","key":"2542_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.18632\/oncotarget.114","volume":"1","author":"AM Martelli","year":"2010","unstructured":"Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase\/Akt\/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010;1(2):89\u2013103.","journal-title":"Oncotarget"},{"issue":"4","key":"2542_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd4505","volume":"14","author":"M Bhat","year":"2015","unstructured":"Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Rev Drug Discov. 2015;14(4):261\u201378.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2542_CR23","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1073\/pnas.1011477108","volume":"108","author":"R Cencic","year":"2011","unstructured":"Cencic R, Hall DR, Robert F, Du Y, Min J, Li L, et al. Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A. 2011;108(3):1046\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2542_CR24","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/leu.2011.57","volume":"25","author":"BC Kraljacic","year":"2011","unstructured":"Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 2011;25(7):1197\u2013200.","journal-title":"Leukemia"},{"key":"2542_CR25","doi-asserted-by":"publisher","first-page":"e1603","DOI":"10.1038\/cddis.2014.542","volume":"6","author":"A Modelska","year":"2015","unstructured":"Modelska A, Turro E, Russell R, Beaton J, Sbarrato T, Spriggs K, et al. The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape. Cell Death Dis. 2015;6:e1603.","journal-title":"Cell Death Dis"},{"issue":"24","key":"2542_CR26","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1101\/gad.1604407","volume":"21","author":"HG Wendel","year":"2007","unstructured":"Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21(24):3232\u20137.","journal-title":"Genes Dev"},{"issue":"2","key":"2542_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","volume":"22","author":"A Efeyan","year":"2010","unstructured":"Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010;22(2):169\u201376.","journal-title":"Curr Opin Cell Biol"},{"issue":"10","key":"2542_CR28","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/leu.2014.93","volume":"28","author":"KP Callahan","year":"2014","unstructured":"Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, et al. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia. 2014;28(10):1960\u20138.","journal-title":"Leukemia"},{"issue":"19","key":"2542_CR29","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1182\/blood-2008-09-175430","volume":"113","author":"DM Lucas","year":"2009","unstructured":"Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009;113(19):4656\u201366.","journal-title":"Blood"},{"issue":"1","key":"2542_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13046-019-1053-y","volume":"38","author":"X Ma","year":"2019","unstructured":"Ma X, Li B, Liu J, Fu Y, Luo Y. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. J Exp Clin Cancer Res. 2019;38(1):66.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2542_CR31","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1038\/s41467-019-13086-5","volume":"10","author":"K Chan","year":"2019","unstructured":"Chan K, Robert F, Oertlin C, Kapeller-Libermann D, Avizonis D, Gutierrez J, et al. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nat Commun. 2019;10(1):5151.","journal-title":"Nat Commun"},{"issue":"8","key":"2542_CR32","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.celrep.2020.02.002","volume":"30","author":"J Chu","year":"2020","unstructured":"Chu J, Zhang W, Cencic R, O\u2019Connor PBF, Robert F, Devine WG, et al. Rocaglates induce gain-of-function alterations to eIF4A and eIF4F. Cell Rep. 2020;30(8):2481\u20138 e5.","journal-title":"Cell Rep"},{"issue":"11","key":"2542_CR33","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.chembiol.2019.08.008","volume":"26","author":"J Chu","year":"2019","unstructured":"Chu J, Zhang W, Cencic R, Devine WG, Beglov D, Henkel T, et al. Amidino-rocaglates: a potent class of eIF4A inhibitors. Cell Chem Biol. 2019;26(11):1586\u201393 e3.","journal-title":"Cell Chem Biol"},{"issue":"1","key":"2542_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4049\/jimmunol.174.1.180","volume":"174","author":"LX Wu","year":"2005","unstructured":"Wu LX, La Rose J, Chen L, Neale C, Mak T, Okkenhaug K, et al. CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase\/mammalian target of rapamycin pathway. J Immunol. 2005;174(1):180\u201394.","journal-title":"J Immunol"},{"key":"2542_CR35","doi-asserted-by":"publisher","first-page":"665291","DOI":"10.3389\/fonc.2021.665291","volume":"11","author":"V Dembitz","year":"2021","unstructured":"Dembitz V, Gallipoli P. The role of metabolism in the development of personalized therapies in acute myeloid leukemia. Front Oncol. 2021;11:665291.","journal-title":"Front Oncol"},{"issue":"5982","key":"2542_CR36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1126\/science.1187532","volume":"328","author":"RJ Dowling","year":"2010","unstructured":"Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science. 2010;328(5982):1172\u20136.","journal-title":"Science"},{"issue":"5","key":"2542_CR37","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.cmet.2013.10.001","volume":"18","author":"M Morita","year":"2013","unstructured":"Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T, et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab. 2013;18(5):698\u2013711.","journal-title":"Cell Metab"},{"issue":"3","key":"2542_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell. 2013;12(3):329\u201341.","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2542_CR39","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","volume":"7","author":"T Farge","year":"2017","unstructured":"Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7(7):716\u201335.","journal-title":"Cancer Discov"},{"issue":"3","key":"2542_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","volume":"34","author":"AL Boyd","year":"2018","unstructured":"Boyd AL, Aslostovar L, Reid J, Ye W, Tanasijevic B, Porras DP, et al. Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence. Cancer Cell. 2018;34(3):483\u201398 e5.","journal-title":"Cancer Cell"},{"issue":"3","key":"2542_CR41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cmet.2020.07.009","volume":"32","author":"N van Gastel","year":"2020","unstructured":"van Gastel N, Spinelli JB, Sharda A, Schajnovitz A, Baryawno N, Rhee C, et al. Induction of a timed metabolic collapse to overcome cancer chemoresistance. Cell Metabol. 2020;32(3):391\u2013403.e6.","journal-title":"Cell Metabol"},{"issue":"9","key":"2542_CR42","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1038\/s41375-021-01308-z","volume":"35","author":"Y Nishida","year":"2021","unstructured":"Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, et al. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML. Leukemia. 2021;35(9):2469\u201381.","journal-title":"Leukemia"},{"issue":"21","key":"2542_CR43","doi-asserted-by":"publisher","first-page":"15727","DOI":"10.1021\/acs.jmedchem.1c01014","volume":"64","author":"CJ Zerio","year":"2021","unstructured":"Zerio CJ, Cunningham TA, Tulino AS, Alimusa EA, Buckley TM, Moore KT, et al. Discovery of an eIF4A inhibitor with a novel mechanism of action. J Med Chem. 2021;64(21):15727\u201346.","journal-title":"J Med Chem"},{"issue":"1","key":"2542_CR44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1021\/jm201263k","volume":"55","author":"CM Rodrigo","year":"2012","unstructured":"Rodrigo CM, Cencic R, Roche SP, Pelletier J, Porco JA. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies. J Med Chem. 2012;55(1):558\u201362.","journal-title":"J Med Chem"},{"issue":"32","key":"2542_CR45","doi-asserted-by":"publisher","first-page":"12891","DOI":"10.1021\/jacs.9b06446","volume":"141","author":"W Zhang","year":"2019","unstructured":"Zhang W, Chu J, Cyr AM, Yueh H, Brown LE, Wang TT, et al. Intercepted retro-nazarov reaction: syntheses of amidino-rocaglate derivatives and their biological evaluation as eIF4A inhibitors. J Am Chem Soc. 2019;141(32):12891\u2013900.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"2542_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2015.05.049","volume":"162","author":"ML Truitt","year":"2015","unstructured":"Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM, et al. Differential requirements for eIF4E dose in normal development and cancer. Cell. 2015;162(1):59\u201371.","journal-title":"Cell"},{"issue":"7104","key":"2542_CR47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818\u201322.","journal-title":"Nature"},{"issue":"17","key":"2542_CR48","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.1182\/bloodadvances.2022007250","volume":"6","author":"FE Mercier","year":"2022","unstructured":"Mercier FE, Shi J, Sykes DB, Oki T, Jankovic M, Man CH, et al. In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. Blood Adv. 2022;6(17):5072\u201384.","journal-title":"Blood Adv"},{"issue":"9","key":"2542_CR49","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/sj.leu.2400768","volume":"11","author":"Y Matsuo","year":"1997","unstructured":"Matsuo Y, MacLeod R, Uphoff C, Drexler H, Nishizaki C, Katayama Y, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins (11; 9)(q23; p22p23). Leukemia. 1997;11(9):1469\u201377.","journal-title":"Leukemia"},{"issue":"1","key":"2542_CR50","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2016.08.057","volume":"167","author":"DB Sykes","year":"2016","unstructured":"Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167(1):171\u201386.e15.","journal-title":"Cell"},{"issue":"8","key":"2542_CR51","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/bioinformatics\/btaa102","volume":"36","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2020;36(8):2645.","journal-title":"Bioinformatics"},{"issue":"W1","key":"2542_CR52","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","volume":"48","author":"A Ianevski","year":"2020","unstructured":"Ianevski A, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. Nucleic Acids Res. 2020;48(W1):W488\u2013W93.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2542_CR53","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1101\/gr.197566.115","volume":"26","author":"V Gandin","year":"2016","unstructured":"Gandin V, Masvidal L, Hulea L, Gravel S-P, Cargnello M, McLaughlan S, et al. nanoCAGE reveals 5\u2032 UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. Genome Res. 2016;26(5):636\u201348.","journal-title":"Genome Res"},{"key":"2542_CR54","doi-asserted-by":"crossref","unstructured":"Gandin V, Sikstrom K, Alain T, Morita M, McLaughlan S, Larsson O, et al. Polysome fractionation and analysis of mammalian translatomes on a genome-wide scale.\u00a0J Vis Exp. 2014;(87):51455.","DOI":"10.3791\/51455"},{"issue":"4","key":"2542_CR55","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.neo.2021.02.003","volume":"23","author":"D Papadopoli","year":"2021","unstructured":"Papadopoli D, Uchenunu O, Palia R, Chekkal N, Hulea L, Topisirovic I, et al. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin. Neoplasia. 2021;23(4):391\u20139.","journal-title":"Neoplasia"},{"issue":"17","key":"2542_CR56","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1074\/jbc.M116.774471","volume":"292","author":"SA Mookerjee","year":"2017","unstructured":"Mookerjee SA, Gerencser AA, Nicholls DG, Brand MD. Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements. J Biol Chem. 2017;292(17):7189\u2013207.","journal-title":"J Biol Chem"},{"issue":"7","key":"2542_CR57","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1515\/hsz-2016-0107","volume":"397","author":"J Ryan","year":"2016","unstructured":"Ryan J, Montero J, Rocco J, Letai A. iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry. Biol Chem. 2016;397(7):671\u20138.","journal-title":"Biol Chem"},{"issue":"5","key":"2542_CR58","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/cancers13051002","volume":"13","author":"RN Rys","year":"2021","unstructured":"Rys RN, Wever CM, Geoffrion D, Goncalves C, Ghassemian A, Brailovski E, et al. Apoptotic blocks in primary non-Hodgkin B cell lymphomas identified by BH3 profiling. Cancers. 2021;13(5):1002.","journal-title":"Cancers"},{"issue":"12","key":"2542_CR59","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1002\/eji.202170126","volume":"51","author":"A Cossarizza","year":"2021","unstructured":"Cossarizza A, Chang HD, Radbruch A, Abrignani S, Addo R, Akdis M, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol. 2021;51(12):2708\u20133145.","journal-title":"Eur J Immunol"},{"key":"2542_CR60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/(SICI)1097-0320(19981215)34:6<280::AID-CYTO6>3.0.CO;2-H","volume":"34","author":"M Keeney","year":"1998","unstructured":"Keeney M, Gratama J, Chin-Yee I, Sutherland D. Isotype controls in the analysis of lymphocytes and CD34+ stem and progenitor cells by flow cytometry\u2014time to let go! Cytometry (Communications in Clinical Cytometry). 1998;34:280\u20133.","journal-title":"Cytometry (Communications in Clinical Cytometry)"},{"issue":"7","key":"2542_CR61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1101\/gad.1771409","volume":"23","author":"J Zuber","year":"2009","unstructured":"Zuber J, Radtke I, Pardee TS, Zhao Z, Rappaport AR, Luo W, et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 2009;23(7):877\u201389.","journal-title":"Genes Dev"},{"key":"2542_CR62","doi-asserted-by":"crossref","unstructured":"Skofler C, Kleinegger F, Krassnig S, Birkl-Toeglhofer AM, Singer G, Till H, et al. Eukaryotic translation initiation factor 4AI: a potential novel target in neuroblastoma.\u00a0Cells. 2021;10(2):301.","DOI":"10.3390\/cells10020301"},{"issue":"11","key":"2542_CR63","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1158\/1535-7163.MCT-19-0162","volume":"18","author":"T Kong","year":"2019","unstructured":"Kong T, Xue Y, Cencic R, Zhu X, Monast A, Fu Z, et al. eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4\/6 inhibition in cancer. Mol Cancer Ther. 2019;18(11):2158\u201370.","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"2542_CR64","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/onc.2012.236","volume":"32","author":"C Jin","year":"2013","unstructured":"Jin C, Rajabi H, Rodrigo CM, Porco JA Jr, Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene. 2013;32(17):2179\u201388.","journal-title":"Oncogene"},{"issue":"4","key":"2542_CR65","doi-asserted-by":"publisher","first-page":"101100","DOI":"10.1016\/j.beha.2019.101100","volume":"32","author":"CT Jordan","year":"2019","unstructured":"Jordan CT. Can we selectively target AML stem cells? Best Pract Res Clin Haematol. 2019;32(4):101100.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"2542_CR66","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/s41418-018-0209-1","volume":"26","author":"NS Anstee","year":"2019","unstructured":"Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, et al. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Cell Death Differ. 2019;26(7):1316\u201331.","journal-title":"Cell Death Differ"},{"issue":"2","key":"2542_CR67","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","volume":"12","author":"J Deng","year":"2007","unstructured":"Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12(2):171\u201385.","journal-title":"Cancer Cell"},{"issue":"3","key":"2542_CR68","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362\u201375.","journal-title":"Cancer Discov"},{"issue":"20","key":"2542_CR69","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/0008-5472.CAN-19-0515","volume":"79","author":"M Hosseini","year":"2019","unstructured":"Hosseini M, Rezvani HR, Aroua N, Bosc C, Farge T, Saland E, et al. Targeting myeloperoxidase disrupts mitochondrial redox balance and overcomes cytarabine resistance in human acute myeloid leukemia. Cancer Res. 2019;79(20):5191\u2013203.","journal-title":"Cancer Res"},{"issue":"2","key":"2542_CR70","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","volume":"151","author":"TT Vo","year":"2012","unstructured":"Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012;151(2):344\u201355.","journal-title":"Cell"},{"issue":"1","key":"2542_CR71","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1021\/acs.jproteome.0c00690","volume":"20","author":"R Zhang","year":"2021","unstructured":"Zhang R, Engel AL, Wang Y, Li B, Shen W, Gillies MC, et al. Inhibition of mitochondrial respiration impairs nutrient consumption and metabolite transport in human retinal pigment epithelium. J Proteome Res. 2021;20(1):909\u201322.","journal-title":"J Proteome Res"},{"issue":"6","key":"2542_CR72","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.immuni.2007.05.013","volume":"26","author":"RR Hardy","year":"2007","unstructured":"Hardy RR, Kincade PW, Dorshkind K. The protean nature of cells in the B lymphocyte lineage. Immunity. 2007;26(6):703\u201314.","journal-title":"Immunity"},{"issue":"5","key":"2542_CR73","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","volume":"27","author":"CL Jones","year":"2020","unstructured":"Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27(5):748\u201364 e4.","journal-title":"Cell Stem Cell"},{"issue":"10","key":"2542_CR74","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.stem.2021.06.004","volume":"28","author":"A Subedi","year":"2021","unstructured":"Subedi A, Liu Q, Ayyathan DM, Sharon D, Cathelin S, Hosseini M, et al. Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis. Cell Stem Cell. 2021;28(10):1851\u201367.e8.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"2542_CR75","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D\u2019Alessandro A, Winters A, et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat Cancer. 2020;1(12):1176\u201387.","journal-title":"Nat Cancer"},{"issue":"3","key":"2542_CR76","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/molecules22030499","volume":"22","author":"Z Li","year":"2017","unstructured":"Li Z, Guo JR, Chen QQ, Wang CY, Zhang WJ, Yao MC, et al. Exploring the antitumor mechanism of high-dose cytarabine through the metabolic perturbations of ribonucleotide and deoxyribonucleotide in human promyelocytic leukemia HL-60 cells. Molecules. 2017;22(3):499.","journal-title":"Molecules"},{"issue":"4","key":"2542_CR77","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3324\/haematol.2020.246843","volume":"106","author":"H Abacka","year":"2021","unstructured":"Abacka H, Hansen JS, Huang P, Venskutonyte R, Hyrenius-Wittsten A, Poli G, et al. Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance. Haematologica. 2021;106(4):1163\u20136.","journal-title":"Haematologica"},{"key":"2542_CR78","doi-asserted-by":"crossref","unstructured":"Bjelosevic S, Gruber E, Newbold A, Kats LM, Shembrey C, Abrehart TC, et al. Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia.\u00a0Cancer Discov. 2021;11(6):1582-1599.","DOI":"10.1158\/2159-8290.CD-20-0738"},{"issue":"7","key":"2542_CR79","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","volume":"39","author":"SK Joshi","year":"2021","unstructured":"Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. 2021;39(7):999\u20131014 e8.","journal-title":"Cancer Cell"},{"issue":"11","key":"2542_CR80","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","volume":"2","author":"C Bosc","year":"2021","unstructured":"Bosc C, Saland E, Bousard A, Gadaud N, Sabatier M, Cognet G, et al. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia. Nat Cancer. 2021;2(11):1204\u201323.","journal-title":"Nat Cancer"},{"issue":"1","key":"2542_CR81","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40164-021-00201-w","volume":"10","author":"E Rorby","year":"2021","unstructured":"Rorby E, Adolfsson J, Hultin E, Gustafsson T, Lotfi K, Cammenga J, et al. Multiplexed single-cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells. Exp Hematol Oncol. 2021;10(1):7.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2542_CR82","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2003-06-1969","volume":"103","author":"R Zheng","year":"2004","unstructured":"Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103(1):267\u201374.","journal-title":"Blood"},{"issue":"2","key":"2542_CR83","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/cells9020404","volume":"9","author":"S Mirabilii","year":"2020","unstructured":"Mirabilii S, Ricciardi MR, Tafuri A. mTOR regulation of metabolism in hematologic malignancies. Cells. 2020;9(2):404.","journal-title":"Cells"},{"issue":"11","key":"2542_CR84","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1541-7786.MCR-13-0172","volume":"11","author":"LL Liu","year":"2013","unstructured":"Liu LL, Long ZJ, Wang LX, Zheng FM, Fang ZG, Yan M, et al. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism. Mol Cancer Res. 2013;11(11):1326\u201336.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"2542_CR85","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/blood.2019898114","volume":"134","author":"CL Jones","year":"2019","unstructured":"Jones CL, Stevens BM, D\u2019Alessandro A, Culp-Hill R, Reisz JA, Pei S, et al. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. Blood. 2019;134(4):389\u201394.","journal-title":"Blood"},{"issue":"3-4","key":"2542_CR86","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1089\/ars.2005.7.508","volume":"7","author":"AJ Kowaltowski","year":"2005","unstructured":"Kowaltowski AJ, Fiskum G. Redox mechanisms of cytoprotection by Bcl-2. Antioxid Redox Signal. 2005;7(3-4):508\u201314.","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"2542_CR87","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.yjmcc.2009.02.021","volume":"46","author":"AP Halestrap","year":"2009","unstructured":"Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol. 2009;46(6):821\u201331.","journal-title":"J Mol Cell Cardiol"},{"issue":"369","key":"2542_CR88","doi-asserted-by":"publisher","first-page":"369ra175","DOI":"10.1126\/scitranslmed.aae0348","volume":"8","author":"GR Anderson","year":"2016","unstructured":"Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, et al. PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. Sci Transl Med. 2016;8(369):369ra175.","journal-title":"Sci Transl Med"},{"issue":"1","key":"2542_CR89","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.leu.2402740","volume":"17","author":"H Quentmeier","year":"2003","unstructured":"Quentmeier H, Reinhardt J, Zaborski M, Drexler HG. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003;17(1):120\u20134.","journal-title":"Leukemia"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02542-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02542-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02542-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T03:05:09Z","timestamp":1670555109000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02542-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2542"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02542-8","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Animal Care Committee at McGill University (protocol number: 2018-8011). All the experiments comply with the guidelines set by the Canadian Council of Animal Care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors read and approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors do not have competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}